Dark Streaming/Mobile Old Site Home Daily Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:06:47 EDT Mon 27 Mar 2023
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:VIRX from 2022-03-28 to 2023-03-27 - 25 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2023-03-13 16:05U:VIRXNews ReleaseViracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
2023-03-08 16:05U:VIRXNews ReleaseViracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference
2023-02-07 16:05U:VIRXNews ReleaseViracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
2023-01-19 08:30U:VIRXNews ReleaseViracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma
2023-01-08 13:00U:VIRXNews ReleaseViracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives
2022-11-30 18:10U:VIRXNews ReleaseViracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress
2022-11-21 17:08U:VIRXNews ReleaseViracta Therapeutics Announces New Employment Inducement Grant
2022-11-14 16:42U:VIRXNews ReleaseViracta Therapeutics Announces New Employment Inducement Grant
2022-11-10 16:05U:VIRXNews ReleaseViracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs
2022-11-02 16:05U:VIRXNews ReleaseViracta Therapeutics to Present at Upcoming Investor Conferences
2022-09-19 16:30U:VIRXNews ReleaseViracta Therapeutics Announces New Employment Inducement Grant
2022-09-19 08:00U:VIRXNews ReleaseViracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth
2022-09-07 09:00U:VIRXNews ReleaseViracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell Lymphoma
2022-08-16 16:15U:VIRXNews ReleaseViracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases
2022-08-11 09:00U:VIRXNews ReleaseViracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors
2022-08-09 08:30U:VIRXNews ReleaseViracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates
2022-06-13 16:15U:VIRXNews ReleaseViracta Therapeutics President and Chief Executive Officer Dr. Ivor Royston Receives the Science History Institute's Biotechnology Heritage Award
2022-06-02 08:30U:VIRXNews ReleaseViracta Therapeutics Provides an Update on the Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and Announces Upcoming Poster Presentation at the ASCO Annual Meeting
2022-06-01 16:15U:VIRXNews ReleaseViracta Therapeutics to Present at the Jefferies Healthcare Conference
2022-05-23 08:00U:VIRXNews ReleaseEnlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
2022-05-13 16:05U:VIRXNews ReleaseViracta Therapeutics Announces New Employment Inducement Grant
2022-05-11 16:05U:VIRXNews ReleaseViracta Therapeutics to Present at Upcoming May Investor Conferences
2022-05-10 16:05U:VIRXNews ReleaseViracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates
2022-04-20 11:58U:VIRXNews ReleaseViracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment of Advanced Epstein-Barr Virus-Positive Solid Tumors
2022-04-07 10:13U:VIRXNews ReleaseViracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference